[A24-98] Enfortumab vedotin (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 11.12.2024
Project no.:
A24-98
Commission:
Commission awarded on 24.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
| Project no. | Title | Status |
|---|---|---|
| A22-61 | Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |